Skip to content
Genesis Innovation Group
Menu
  • Home
  • About Us
  • Device Development
  • Investing
  • News
  • Contact Us

Embody Receives $2.5 Million Phase II Research Award

Posted on January 14, 2020January 21, 2020 by Genesis Innovation Group

Embody, a cultivate(MD) portfolio company, is receiving a $2.5 million Phase II Small Business Innovation Research award through the Defense Advanced Research Projects Agency (DARPA).

This brings Embody’s total DARPA funding to $14.35 million.

Read the full release

Posted in News

Latest News

  • Embody, Inc. Announces $9.3 M Series A Funding Round
  • Shoulder Innovations Presentation with Life Science Intelligence
  • Embody Receives $2.5 Million Phase II Research Award
  • Genesis Innovation Group’s cultivate(MD)™ Capital Fund II, LP Announces Participation in Virtual Incision’s $20 Million Financing to Advance First-of-its-Kind Mini-Robot for General Surgery Abdominal Procedures
  • Virtual Incision Announces $20 Million Financing
cultivatemd medical device venture capital wmt exit

Genesis Services

  • Medical Device Development
  • Engineering
  • Regulatory
  • Operations
  • Finance
  • Commercialization

Investing

  • For Investors
  • For Companies Seeking Investment
  • Portfolio

News & Updates

  • Embody, Inc. Announces $9.3 M Series A Funding Round
  • Shoulder Innovations Presentation with Life Science Intelligence
  • Embody Receives $2.5 Million Phase II Research Award

Contact Us

Genesis Innovation Group
13827 Port Sheldon St.
Holland, MI 49424

(616) 294-1026

Copyright © 2020 Genesis Innovation Group  
This website may contain forward-looking statements within the meaning of the relevant sections of the Securities Act. The words “believes”, “anticipates”, “expects”, “plans”, “intends” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements and statements of expectations, plans and intent are subject to a number of risks and uncertainties. Genesis Innovation Group, LLC’s actual future results may differ materially or adversely from those described in the forward-looking statements as a result of, among other things, uncertainties and other matters described in this website, generally. Genesis Innovation Group, LLC undertakes no obligation to release the results of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances. Genesis Innovation Group, LLC cautions the reader, however, that the identified uncertainties and other cautionary language contained herein may not be exhaustive. Nothing in this website shall be construed to be an offer to sell or a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose.